share_log

HC Wainwright & Co. Maintains Buy on Akero Therapeutics, Raises Price Target to $50

HC Wainwright & Co. Maintains Buy on Akero Therapeutics, Raises Price Target to $50

HC Wainwright & Co.維持對Akero Therapeutics的買入,將目標股價上調至50美元
Benzinga ·  03/05 06:46

HC Wainwright & Co. analyst Ed Arce maintains Akero Therapeutics (NASDAQ:AKRO) with a Buy and raises the price target from $43 to $50.

HC Wainwright & Co. 分析師埃德·阿爾塞維持Akero Therapeutics(納斯達克股票代碼:AKRO)的買入並將目標股價從43美元上調至50美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論